CTOs on the Move


 
Vybion is a Ithaca, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vybion.com
  • 33 Thornwood Dr
    Ithaca, NY USA 14850
  • Phone: 607.266.0860

Executives

Name Title Contact Details

Similar Companies

Lorian Home Health

Lorian Home Health is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Psychemedics

Psychemedics (NASDAQ: PMD) is the world`s leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 30 years and thousands of corporations worldwide currently rely on Psychemedics` patented hair analysis technology for their pre-employment and employee drug screening. Psychemedics` clients include over 10% of the Fortune 500, some of the largest police departments in America, Federal Reserve Banks, and schools.

ImmusanT

ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.

Hookipa Pharma

Hookipa Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body`s immune system. HOOKIPA`s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA`s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA`s VaxWave®-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.